N-Hydroxymethylnicotinamide

N-Hydroxymethylnicotinamide

SCHEMBL352358

O=C(NCO)c1cccnc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 1.00
HDAC1 Q13547 1/20 0.65
HDAC6 Q9UBN7 1/20 0.65
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
NPC1 O15118 3/20 0.62
RAB9A P51151 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
TSHR P16473 1/20 0.60
EPHX2 P34913 3/20 0.59
CYP2C9 P11712 2/20 0.59
CYP2C19 P33261 2/20 0.59
LMNA P02545 1/20 0.59
HIF1A Q16665 1/20 0.59
MAPT P10636 1/20 0.57
ALDH1A1 P00352 1/20 0.57
ROCK2 O75116 1/20 0.57
ROCK1 Q13464 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25328235 0.87 THRB (0.77) THRBHDAC1HDAC6MEN1KMT2A
SCHEMBL14415899 0.87 THRB (0.77) THRBHDAC1HDAC6MEN1KMT2A
SCHEMBL30664046 0.86 THRB (0.75) THRBHDAC1HDAC6MEN1KMT2A
Nicotinuric Acid SCHEMBL351962 0.86 THRB (0.75) THRBHDAC1HDAC6MEN1KMT2A
SCHEMBL3864600 0.86 THRB (0.75) THRBHDAC1HDAC6MEN1KMT2A
Nicotinuric Acid SCHEMBL30183567 0.86 THRB (0.75) THRBHDAC1HDAC6MEN1KMT2A
SCHEMBL62572 0.86 THRB (0.75) THRBHDAC1HDAC6MEN1KMT2A
SCHEMBL20663433 0.85 THRB (0.73) THRBHDAC1HDAC6MEN1KMT2A
SCHEMBL1687071 0.84 THRB (0.73) THRBHDAC1HDAC6MEN1KMT2A
Hydrochloric Acid SCHEMBL7321595 0.84 THRB (0.73) THRBHDAC1HDAC6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 744 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094660-A Composition in the form of an oil-in-water emulsion 2026-05-26 CN claimed
EP-4687829-A1 COMPOSITION FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2026-02-11 EP claimed
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME OREAL (FR) 2025-12-18 US claimed
US-20250271424-A1 TARGET INTERFERENCE SUPPRESSED ANTI-DRUG ANTIBODY ASSAY HOFFMANN-LA ROCHE INC. 2025-08-28 US claimed
WO-2025091220-A2 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
WO-2025091239-A1 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
EP-4528277-A2 TARGET INTERFERENCE SUPPRESSED ANTI-DRUG ANTIBODY ASSAY F. Hoffmann-La Roche AG (CH) 2025-03-26 EP claimed
CN-119680635-A Ionic liquid catalyst for producing renewable fuel from waste grease and preparation method and application thereof 中国科学院青岛生物能源与过程研究所 2025-03-25 CN claimed
CN-119654151-A Composition for caring skin 莱雅公司 2025-03-18 CN claimed
CN-119630382-A Solubilization of thiopyridone compounds and compositions containing same 莱雅公司 2025-03-14 CN claimed
EP-0896522-B1 METHODS OF REGULATING SKIN APPEARANCE WITH VITAMIN B 3 COMPOUND PROCTER & GAMBLE (US) 2003-10-22 EP claimed
US-6383476-B1 Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent THE PROCTER & GAMBLE COMPANY 2002-05-07 US claimed
WO-2001079212-A1 SILICON DERIVATIVES OF FRAGRANT, FLAVOURING AND MEDICINAL SUBSTANCES KIREEV VYACHESLAV VASILIEVICH (RU) 2001-10-25 WO claimed
EP-0705868-B1 Regenerated cellulose-based materials having a high bleach resistance, and process for preparing them ELYSEES BALZAC FINANCIERE (FR) 1999-12-08 EP claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed
EP-0792146-A1 INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES HEMASURE, INC. (US) 1997-09-03 EP claimed
WO-1997002028-A1 INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES HEMASURE, INC. (US) 1997-01-23 WO claimed
EP-0705868-A1 Regenerated cellulose-based materials having a high bleach resistance, and process for preparing them FINANCIERE ELYSEES BALZAC (FR) 1996-04-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME TBCB, CCNB3, CYP24A1 THRB 494/4885HDAC1 3263/4885HDAC6 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.